From July 25 to 27, 2025 Annual Meeting of the Dermatological Pharmacy Committee was grandly held in Shijiazhuang, co-hosted by the Dermatological Pharmacy Professional Committee of Hebei Pharmaceutical Association and the First Hospital of Hebei Medical University. During the conference, CSPC Innovation co-organized the Urticaria Session, where renowned dermatology experts from across China gathered for academic exchanges on advances in the diagnosis and treatment of urticaria, interpretation of the latest guidelines, and the therapeutic advantages of CSPC Omalizumab.

During the Urticaria Session, Professor Zhang Guoqiang from the First Hospital of Hebei Medical University and Professor Xu Jinhua from Huashan Hospital, Fudan University were invited as chairpersons. Professor Liu Lijuan from the First Hospital of Hebei Medical University, Professor Duan Xinsuo from the Affiliated Hospital of Chengde Medical University, and Professor Shen Yanyun from Huashan Hospital, Fudan University served as speakers, who delivered detailed interpretations on the topics of Expert Consensus on Targeted Therapy of Chronic Spontaneous Urticaria, Advances in the Diagnosis and Treatment of Urticaria, and Construction of Urticaria-Specific Clinics respectively.The Expert Consensus recommends that omalizumab should be maintained for at least 6 to 12 months before considering dose reduction or discontinuation in the treatment of chronic spontaneous urticaria, reaffirming the necessity of long-term treatment with omalizumab. Advances in Diagnosis and Treatment also clarified that Enyitan®, as the first omalizumab biosimilar approved in China, not only achieves equivalent clinical efficacy to the reference drug, but also costs 20% less per injection, improving drug accessibility and providing a superior treatment option for patients with chronic spontaneous urticaria.At the end of the session, the participating experts held in-depth discussions on topics including how omalizumab prolongs the duration of treatment (DOT) for patients, the future development trends of biological agents in the field of urticaria, and clinical experience in the application of omalizumab. The event featured active on-site interaction and a strong academic atmosphere, offering valuable references for clinical decision-making.